Nexo Therapeutics Secures $60 Million in Series A Funding to Revolutionize Cancer Treatment

Nexo Therapeutics, an innovative small molecule oncology company, has successfully raised $60 million in a recent funding round aimed at accelerating its mission to discover and develop groundbreaking therapies for cancer patients facing significant unmet medical needs. Founded and led by Andrew Phillips, PhD, Nexo Therapeutics is at the forefront of cancer drug development, leveraging the unique combination of covalent ligand discovery, chemical biology, and expertise in medicinal chemistry to tackle the fundamental drivers of cancer through pioneering approaches. With state-of-the-art facilities in both Golden, CO, and Watertown, MA, Nexo is well-positioned to push the boundaries of oncology research. This latest funding will primarily be allocated towards advancing their lead drug candidates through clinical trials, enhancing the company’s robust pipeline, and facilitating further research into innovative therapeutic modalities. As Nexo Therapeutics continues its commitment to delivering meaningful therapies, the infusion of capital not only strengthens the company's financial foundation but also underscores the growing confidence from investors in their groundbreaking work. By focusing on the patients who currently have limited options, Nexo is dedicated to transforming the landscape of cancer treatment and improving outcomes for those in need. For additional insights into Nexo Therapeutics’ game-changing approach and their journey in the fight against cancer, please visit www.nexotx.com.